Oxford, AstraZeneca to resume coronavirus vaccine trial
LONDON – Oxford University says trials of a coronavirus vaccine that it is developing with pharmaceutical company AstraZeneca will resume, days after being paused due to a reported side-effect in a patient in the U.K. The study had been previously stopped in July for several days after a participant who got the vaccine developed neurological symptoms; it turned out to be an undiagnosed case of multiple sclerosis that was unrelated to the vaccine. Late last month, AstraZeneca began recruiting 30,000 people in the U.S. for its largest study of the vaccine. It also is testing the vaccine in thousands of people in Britain, and in smaller studies in Brazil and South Africa. Dr. Soumya Swaminathan, the World Health Organization’s chief scientist, said the U.N. health agency wasn’t overly concerned by the pause in the Oxford and AstraZeneca vaccine trial, describing it as “a wake-up call” to the global community about the inevitable ups and downs of medical research.